Allogene's IPO is the best biotech public offering in more than a decade.
adrian825—Getty Images/iStockphoto
By Sy Mukherjee
October 11, 2018

Biotech’s red-hot IPO streak shows no signs of slowing down. In fact, on Thursday, cancer drug maker Allogene Therapeutics pulled off the biggest public offering in at least a decade (and one of the most lucrative, ever, period). The firm raised $324 million in an offering that pegs the company’s market value at an eye-popping $2 billion-plus. Allogene stock rose more than 30% in its first day of trading.

The last time a firm even came close to that was Alzheimer’s drug developer Axovant’s $315 million raise in 2015. It should be noted that Axovant’s lead pre-clinical drug at the time went on to crash and burn in spectacular fashion a little more than a year ago.

So just what does Allogene do? The firm is developing a different approach to a new form of cancer therapy called CAR-T. This kind of treatment involves re-engineering patients’ own immune cells in order to become targeted cancer killers; the modified cells are then grown in a lab, multiplied, and then re-inserted into patients, and has shown promise for some patients with deadly blood cancers. The first therapies of this kind, from Novartis and Gilead subsidiary Kite Pharma, respectively, were approved last year by the Food and Drug Administration (FDA).

Allogene’s methodology aims to create an “off-the-shelf” version of CAR-T therapy. That is, their treatment, theoretically, could be created from any immune cell donors’ cells rather than having to extract each batch individually from a patient. This would ostensibly cut down on manufacturing and production costs while reducing invasive procedures on cancer patients.

The management team at Allogene, which is led by Arie Belldegrun and David Chang, is likely a large part of the reason for the monster IPO. The pair were previously at Kite Pharma itself, which was sold to Gilead for $12 billion right ahead of its landmark CAR-T treatment approval for Yescarta. The biotech’s off-the-shelf tech was folded in from drug giant Pfizer.

Subscribe to Brainstorm Health Daily, our newsletter about the most exciting health innovations.

SPONSORED FINANCIAL CONTENT

You May Like

EDIT POST